These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 23558673)
21. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial]. Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918 [No Abstract] [Full Text] [Related]
22. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Chiu J; Tang V; Leung R; Wong H; Chu KW; Poon J; Epstein RJ; Yau T Asian Pac J Cancer Prev; 2014 Jan; 14(11):6585-90. PubMed ID: 24377572 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755 [TBL] [Abstract][Full Text] [Related]
25. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. Liu GF; Bair RJ; Bair E; Liauw SL; Koshy M PLoS One; 2014; 9(1):e82642. PubMed ID: 24416146 [TBL] [Abstract][Full Text] [Related]
27. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Lin SH; Wang L; Myles B; Thall PF; Hofstetter WL; Swisher SG; Ajani JA; Cox JD; Komaki R; Liao Z Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1078-85. PubMed ID: 22867894 [TBL] [Abstract][Full Text] [Related]
28. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. Ozden S; Ozgen Z; Ozyurt H; Gemici C; Yaprak G; Tepetam H; Mayadagli A World J Gastroenterol; 2015 Jan; 21(4):1222-33. PubMed ID: 25632196 [TBL] [Abstract][Full Text] [Related]
29. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685 [TBL] [Abstract][Full Text] [Related]
30. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148 [TBL] [Abstract][Full Text] [Related]
32. Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence. Xu C; Xie J; Liang N; Wang J; Qiao L; Luo H; Zhang JX; Zhang J J Cancer Res Ther; 2014 Dec; 10 Suppl():267-71. PubMed ID: 25693933 [TBL] [Abstract][Full Text] [Related]
33. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study. Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer. Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194 [TBL] [Abstract][Full Text] [Related]
35. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362 [TBL] [Abstract][Full Text] [Related]
36. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259 [TBL] [Abstract][Full Text] [Related]
37. Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional 1H-MRI and 23Na-MRI. Haneder S; Michaely HJ; Schoenberg SO; Konstandin S; Schad LR; Siebenlist K; Wertz H; Wenz F; Lohr F; Boda-Heggemann J Strahlenther Onkol; 2012 Dec; 188(12):1146-54. PubMed ID: 23111472 [TBL] [Abstract][Full Text] [Related]
38. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer]. Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429 [TBL] [Abstract][Full Text] [Related]
40. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]